SonoVascular has developed the SonoThrombectomy™ system, a triple-action catheter technology that utilizes microbubble-mediated cavitation to effectively remove clots in a single catheter lab procedure. This solution addresses the significant clinical challenge of venous thromboembolism (VTE), which leads to high rates of morbidity and mortality due to complications from deep vein thrombosis and pulmonary embolism.
Funding
$7.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), presents a significant clinical challenge, leading to high morbidity and mortality rates. Current thrombolysis (pharmacological) and thrombectomy (mechanical) solutions often fall short of delivering optimal patient outcomes. Up to 50% of DVT patients develop long-term complications, including post-thrombotic syndrome (PTS).
Solution
SonoVascular is developing the SonoThrombectomy™ system, a triple-action catheter technology designed to remove clots effectively in a single catheter lab procedure. The system utilizes microbubble-mediated cavitation to debulk clots. The SonoThrombectomy™ system is designed to be safer, more effective, and less expensive than current solutions, with no ICU treatment required.
Target Audience
The primary target audience includes interventional physicians treating patients with venous thromboembolism (VTE), specifically deep vein thrombosis (DVT) and pulmonary embolism (PE).
Features
- Triple-action catheter system for clot removal.
- Microbubble-mediated cavitation for clot debulking.
- Designed for single-session, cath-lab based interventional procedures.